Aarti Drugs Ltd. Financials: Quarterly Results
Revenue
652.88
Cr.
PAT
45.16
Cr.
EBITDA
68.11
Cr.
Aarti Drugs Ltd. Q2FY26 Financial Metrics
| Indicator | Sep-25 | Jun-25 | Mar-25 | Dec-24 | Sep-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 652.79 | 590.51 | 676.76 | 556.60 | 598.33 |
| Total Income From Operations (Cr.) | 652.79 | 590.51 | 676.76 | 556.60 | 598.33 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 68.11 | 59.67 | 80.31 | 59.83 | 54.81 |
| P/L Before Exceptional Items & Tax (Cr.) | 60.41 | 51.11 | 71.15 | 50.76 | 45.88 |
| P/L After Tax from Ordinary Activities (Cr.) | 45.16 | 53.97 | 62.77 | 37.09 | 34.96 |
| Net Profit/Loss For the Period (Cr.) | 45.16 | 53.97 | 62.77 | 37.09 | 34.96 |
| Basic EPS | 4.95 | 5.91 | 6.88 | 4.06 | 3.83 |
FAQs
Aarti Drugs Ltd. announced its quarterly results for Q2 FY2026 on November 10, 2025.
In Q2 FY2026, Aarti Drugs Ltd. are as follows:
Revenue: ₹652.88 crore
Net Profit: ₹45.16 crore.
For Q2 FY2026, Aarti Drugs Ltd. posted ₹652.88 crore in revenue and ₹45.16 crore in net profit.
Past quarterly results for Aarti Drugs Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.